SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-014405
Filing Date
2023-08-10
Accepted
2023-08-10 07:39:02
Documents
49
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q apre-20230630x10q.htm   iXBRL 10-Q 1534123
2 EX-31.1 apre-20230630xex31d1.htm EX-31.1 9716
3 EX-31.2 apre-20230630xex31d2.htm EX-31.2 10537
4 EX-32.1 apre-20230630xex32d1.htm EX-32.1 6698
5 EX-32.2 apre-20230630xex32d2.htm EX-32.2 6712
  Complete submission text file 0001558370-23-014405.txt   4165279

Data Files

Seq Description Document Type Size
6 EX-101.SCH apre-20230630.xsd EX-101.SCH 26793
7 EX-101.CAL apre-20230630_cal.xml EX-101.CAL 30526
8 EX-101.DEF apre-20230630_def.xml EX-101.DEF 108010
9 EX-101.LAB apre-20230630_lab.xml EX-101.LAB 238172
10 EX-101.PRE apre-20230630_pre.xml EX-101.PRE 179731
43 EXTRACTED XBRL INSTANCE DOCUMENT apre-20230630x10q_htm.xml XML 385529
Mailing Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902
Business Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902 267-370-5219
Aprea Therapeutics, Inc. (Filer) CIK: 0001781983 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39069 | Film No.: 231157210
SIC: 2834 Pharmaceutical Preparations